New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
Why now
Thesis: Supports earlier-line myeloma positioning for J&J combo
Catalyst to watch: Regulatory review or trial readouts for earlier lines
Main risk: Model-based analysis may not replicate in trials
Why it matters
Survival analyses for teclistamab plus daratumumab could support earlier-line use, but model-based analyses are not new trial data.
Details
Analysis shows ~87% of patients treated with TECVAYLI® plus DARZALEX FASPRO® as early as second line were estimated to have comparable mortality risk to the general population A separate analysis shows the survival benefit was driven by a 90% reduction in the risk of multiple myeloma...
Sources
- prnewswire · 2026-09-23 13:46 UTC